Pfizer’s oncology pipeline has achieved a second positive phase III trial in HER2-positive breast cancer within roughly a year. This latest success involves TUKYSA, a HER2-targeted tyrosine kinase inhibitor that Pfizer acquired through its $43 billion purchase of Seagen.
In patients with HER2-positive metastatic breast cancer who responded to standard induction therapy, TUKYSA, when administered as a first-line maintenance treatment, significantly extended the time to cancer progression or death compared with placebo. Both TUKYSA and placebo were given alongside the standard maintenance regimen of Roche’s breast cancer drugs HERCEPTIN and PERJETA.
The phase III ...
